Role of Biomarkers in Muscle Pain and Joint Pain in Patients With Solid Tumors Receiving Paclitaxel

Vanderbilt-Ingram Cancer Center5 enrolled

Overview

RATIONALE: Learning about pain in patients with cancer receiving paclitaxel may help plan treatment and may help patients live more comfortably. Studying samples of urine from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to muscle and joint pain. PURPOSE: This phase I trial is studying the role of biomarkers in muscle pain and joint pain in patients with solid tumors receiving paclitaxel.

OBJECTIVES: Primary * To determine the change in urinary prostaglandin E metabolite (PGE-M) level after paclitaxel treatment in patients with a variety of solid tumor malignancies. * To determine whether a change in PGE-M level correlates with paclitaxel dose. * To determine whether the change in urinary PGE-M level correlates with patient reporting of pain, as measured by a visual analog scale and the Brief Pain Inventory short form (BPI-SF). Secondary * To determine whether leukotriene levels are affected by paclitaxel treatment. OUTLINE: At baseline (prior to the first dose of paclitaxel), patients complete a questionnaire about their baseline pain symptoms (including the Brief Pain Inventory short form and the visual analog scale); cigarette smoking status and second-hand smoke exposure; and routine use of any pain medications (including NSAIDs, selective COX-2 inhibitors, and opioid analgesics), corticosteroids, or leukotriene antagonists (montelukast or zafirlukast). Patients also complete questionnaires about their pain daily on days 2-7 after paclitaxel administration. Urine samples are collected at baseline for urinary prostaglandin E metabolite (PGE-M), urinary leukotriene E\_4 (LTE\_4), and urinary cotinine levels and on day 4 for urinary PGE-M and LTE\_4 levels.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Arthralgia Pain

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

DISEASE CHARACTERISTICS: * Solid malignancy of any type * Patients must be scheduled to receive their first dose of paclitaxel at Vanderbilt-Ingram Cancer Center * Any paclitaxel-containing regimen or dosing schedule is allowed PATIENT CHARACTERISTICS: * Not pregnant * Accessible for follow-up * Able to submit urine samples * Able to complete questionnaires PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Outcomes

Primary Outcomes

Change in urinary PGE-M level after paclitaxel treatment

Change in amount of PGE-M in the urine from before administration of paclitaxel to 4 days after treatment.

Time frame: Day 1 before paclitaxel treatment and day 4, after treatment

Secondary Outcomes

Correlation of change in urinary PEG-M level and paclitaxel dose

Inter-relationship between the dose of paclitaxel and the change in level of urinary PEG-M from before treatment compared to day 4 of paclitxel treatment

Time frame: Day 1 before paclitaxel treatment and day 4, after treatment

Correlation of urinary PEG-M level with pain

Inter-relationship between the level of urinary PEG-M level with level of pain, measured from before treatment compared to day 4 after paclitaxel treatment. Pain is measured on the Brief Pain Inventory (BPI). The BPI consists of 7 questions about interference of pain in daily life, answered on a scale of 0 (does not interfere) to 10 (completely interferes). The summary score is the average of the 7 scores, with higher scores indicating greater interference with pain.

Time frame: day 1 before paclitaxel treatment and day 4, after treatment

Change in urinary luekotriene E_4 level after paclitaxel treatment

Inter-relationship be the level of urinary luekotriene E\_4 from before treatment compared to day 4 after paclitaxel treatment